The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
San Diego, United States
11-50 Employees
2019
Claeboe joined ADARx in January 2022 with extensive experience in CGMP drug substance and drug product manufacturing through various stages of clinical development to commercialization. Fisher joined ADARx as our Vice President of Intellectual Property. Our mission is to turn cutting-edge science into life-saving therapeutics. To achieve our mission, we are committed to building an innovative, values-driven organization focused on our people, the advancement of our efficient drug platform and the creation of a deep pipeline of therapeutics to address intractable diseases. ADARx is developing a modality agnostic RNA targeting platform, including oligonucleotides for inhibition, degradation and editing, together with novel oligonucleotide delivery technologies. ADARx is currently focused on diseases in three therapeutic areas: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases. ADARx brings hope for people with intractable disease. The power in our name and of our technology is the ability to identify a wide range of disease targets and choose the best RNA targeting approach to deliver transformative precision therapeutics.
+
Featured
RNA Editing
... ADARx Pharmaceuticals through the RNA editing approach specifically targets an RNA sequence and precisely edits a single base. Learn more here! ...
Planegg, Germany
11-50 Employees
1997
The metabion success story thrives from our creative, innovative and determined employees. We are as diverse as the world and its challenges. Adding an element of competition, the game includes a leaderboard with ranking times. We offer a safe, respectful, flexible and healthy working environment in a thriving, forward-thinking and inspiring company, where every employee can make a difference. Full of freedom for individual development and with a focus on health and well-being. As a global market leader in a dynamic field, we offer a variety of opportunities to support and advance science and research.
+
Featured
Gene editing RNA
... | Gene editing RNA ...
Rishon LeZion, Israel
11-50 Employees
1959
YEDA Technology Transfer from the Weizmann Institute of Science. Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. The innovation ecosystem comprises of three separate but interrelated units within the Institute.
+
Featured
Pharmaceuticals A Platform for Boosting Efficiency of Therapeutic RNA Editing (No. T4-2028)
... recent years, offering a potentially safer alternative to correct single-point mutations. One of the most prevalent forms of RNA editing is Adenosine (A) to Inosine (I) RNA editing, in which adenosines are deaminated into inosines by adenosine deaminase acting on RNA (ADAR) enzymes. ...
Bron, France
1-10 Employees
2002
SQUALI assure pour ses clients une veille sur les législations, les réglementations, les alertes, les retraits ainsi que sur les fraudes et adultération. SQUALI est sollicité pour des prestations de conseil, d’expertise et formations spécifiques aux évaluations des risques en agroalimentaire. Notre mission est d’expertiser, de gérer et de sécuriser l’ensemble des analyses utiles et exigées pour les entreprises agroalimentaires. SQUALI nous donne entière satisfaction, nous avons pleinement confiance dans les services apportés et notamment les conseils sur les analyses à réaliser, les contrôles de fiabilité des résultats d’analyses reçus, la gestion des acheminements des échantillons au départ de nombreux sites en France, les synthèses et interprétations réglementaires. Avec les prestations de SQUALI, nous gagnons un temps précieux mais surtout de l’assurance et de la quiétude ; nous avons aussi commencé à utiliser les services de SQUALI sur des analyses de produits finis comme les MOSH /MOAH, avec la même satisfaction. Au-delà de ces prestations, Squali nous accompagne sur diverses problématiques auxquelles on peut être confronté au quotidien en tant que Responsable Qualité (questions clients, actualités règlementaires, interprétation des résultats, …).Leur réactivité aux questions et leur retour synthétique sur ces sujets sont d’une grande aide et un véritable gain de temps. SQUALI intervient quel que soit le niveau d’exigence et de contraintes auprès des producteurs, des transformateurs et des distributeurs pour assurer une vigilance et un respect des critères de conformité avec des normes, des réglementations et des législations en constante évolution. Squali L’Évènement professionnel des filières de la naturalité Présentation d’Innov’Alliance Innov’Alliance est le pôle de compétitivité leader sur la thématique de la Naturalité.
+
Featured
Molecular biology: RNA editing packs a two punch – SQUALI
... Molecular biology: RNA editing packs a two punch – ...
Durham, United States
Have an innovative idea? We can help you get started! Learn about us, our impact, staff, pipeline of products, and more. As part of the Office for Research and Innovation, we facilitate the transfer of Duke innovations from the lab to the market by engaging with commercial partners to ensure that these innovations have maximum societal impact. These efforts add value and benefit to society and enable future investment in Duke research and innovations. We stand ready to work with you on IP protection, licensing and new venture formation. We can also provide guidance on funding opportunities, partnership strategies and University policies.
+
Featured
Detection and measurement of RNA modifications through targeted RNA editing
... Detection and measurement of RNA modifications through targeted RNA editing — Duke ...
Montpellier, France
11-50 Employees
2013
We are dedicated to leveraging cutting-edge science and technology to contribute to the transformative landscape of mental health, fostering a future where precision and biology converge for the betterment of individuals and society as a whole.”. ALCEDIAG is an innovative diagnostic company specializing in the development and commercialization of blood tests, monitoring solutions, and companion diagnostics, primarily for mental health. These offerings are based upon the company’s distinctive expertise in epigenetics, RNA, and Artificial Intelligence, complemented by neurosciences and psychiatry.
+
Featured
ALCEDIAG biomarkers for better health
... A game changer for bipolar disorder diagnosis using RNA editing-based ...
+
Featured
ILab Systems | Services
... Case Study: A-to-I RNA Editing Uncovers Hidden Signals of Adaptive Genome Evolution in ...
Boston, United States
11-50 Employees
2020
Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease. Ascidian Therapeutics was founded to rewrite RNA by editing and replacing human exons, inspired by this example. By rewriting RNA, Ascidian’s exon editing technology provides the durability of gene therapy without the risks of direct DNA editing or gene replacement, while maintaining endogenous gene expression patterns and levels.
+
Featured
Ascidian Therapeutics | A sea change in RNA therapeutics
... RNA exon editing has the potential to revolutionize our approach to treating human disease. ...
United Kingdom
1-10 Employees
2000
In addition, ELRIG will always be a volunteer led organisation, run by and for the life sciences community, on a not-for-profit basis. ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate, on an open access basis. Although all ELRIG events are free of charge, we rely on our valued exhibitors and sponsors to help fund our future events. ELRIG is a not-for-profit organisation serving the life science & drug discovery communities. ELRIG produces three types of events per year, Conferences, Forums and Networking. The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. Deliver UK leading events, showcasing cutting edge science and technology, that are accessible to all. Drive an open and transparent organisation, with a focus on delivery excellence and financial sustainability.
+
Featured
ELRIG Hot Topic Networking: Cambridge ‘RNA editing’ - ELRIG
... ELRIG Hot Topic Networking: Cambridge ‘RNA editing’ - ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for RNA Editing
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 13 |
| Amount of suitable service providers | 5 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1959 |
| Youngest suiting company | 2021 |
20%
40%
60%
80%
RNA editing is a molecular process through which the nucleotide sequence of an RNA molecule is altered post-transcription, essentially allowing for a diversification of the proteome beyond what is encoded in the DNA. This post-transcriptional modification can involve the insertion, deletion, or substitution of nucleotides within the RNA sequence. One of the most studied types of RNA editing involves the conversion of adenosine to inosine (A-to-I editing) in messenger RNA (mRNA), which can lead to changes in the amino acids encoded by the mRNA, affecting the function of the resulting proteins. In the realm of genetics and molecular biology, the implications of RNA editing are profound, impacting various biological processes and playing a crucial role in the adaptive and evolutionary mechanisms of organisms. For instance, it contributes to the regulation of gene expression, allowing cells to respond to environmental changes rapidly. Furthermore, RNA editing is implicated in the development and function of the nervous system, immune response, and viral replication. Aberrations in RNA editing mechanisms have been associated with a range of diseases, including neurological disorders and cancer, highlighting its significance in both health and disease. The study of RNA editing not only offers insights into fundamental biological processes but also holds potential for therapeutic applications, providing avenues for the development of novel treatments.
1. Increased Specificity and Precision
RNA editing offers unparalleled specificity in modifying the genetic code at the RNA level, allowing for precise alterations without affecting the DNA. This precision ensures targeted therapies and interventions, minimizing off-target effects that are common with DNA editing techniques.
2. Reversibility
Unlike DNA modifications, changes made through RNA editing are not permanent and do not alter the genome. This reversibility is crucial for therapeutic applications, providing a safer approach by reducing long-term risks and allowing adjustments in treatment strategies as needed.
3. Therapeutic Potential
RNA editing has the ability to correct genetic mutations at the RNA level, offering potential treatments for a wide range of diseases, including genetic disorders, cancers, and viral infections. This approach can supplement or replace traditional therapies, providing new avenues for disease management and treatment.
4. Flexibility and Versatility
The process is adaptable to various types of RNA molecules and can be applied to different organisms, making it a versatile tool for research and therapeutic development across diverse fields of study.
While evaluating the different suppliers make sure to check the following criteria:
1. Expertise and Experience
Ensure the supplier has a proven track record in RNA editing technologies, including CRISPR-Cas systems, and has successfully completed projects similar to yours.
2. Quality Control Processes
Verify that the supplier implements rigorous quality control measures at each stage of the RNA editing process to ensure high fidelity and specificity of editing.
3. Customization Capabilities
The supplier should be able to tailor RNA editing solutions to meet your specific project needs, including custom guide RNA design and delivery methods.
4. Turnaround Time
Assess the supplier's ability to deliver results within your project timelines. Prompt delivery without compromising quality is crucial.
5. Cost-Effectiveness
Compare pricing among suppliers, but ensure that cost savings do not come at the expense of quality and reliability.
6. Support and Communication
Choose a supplier that offers excellent customer support, provides clear communication throughout the project, and is readily available to address any concerns.
RNA editing, a revolutionary technique capable of altering RNA sequences post-transcription, presents diverse B2B applications across multiple industries. In the pharmaceutical sector, RNA editing offers a path to novel drug discovery and personalized medicine. By enabling the precise modification of RNA, companies can develop targeted therapies for a range of diseases, including genetic disorders and cancer, tailoring treatments to individual genetic profiles. In agriculture, RNA editing technology is harnessed to engineer crops with enhanced traits such as improved nutritional value, resistance to pests and diseases, and adaptability to adverse environmental conditions. This application not only boosts agricultural productivity but also contributes to food security and sustainability. The biotechnology industry leverages RNA editing for research and development purposes, particularly in gene function studies and therapeutic development. By editing RNA sequences, researchers can elucidate gene functions and identify new targets for therapy, accelerating the pace of innovation in medical treatments and diagnostics. Lastly, in the field of synthetic biology, RNA editing is used to create synthetic organisms or redesign existing biological systems. This has potential applications in environmental conservation, such as bioremediation, and in the production of biofuels and bioplastics, offering eco-friendly alternatives to traditional fossil fuels and plastics.
RNA editing, an innovative approach to gene therapy, is currently positioned at an early to mid-stage Technology Readiness Level (TRL), approximately TRL 3-4. This classification is due to its stage of proof of concept and initial validation in controlled environments. The core principle behind RNA editing involves the precise alteration of RNA sequences in living cells, offering a potential pathway for correcting genetic disorders without permanently modifying the DNA. Despite its groundbreaking promise, RNA editing's placement at this TRL is attributed to several technical challenges. Firstly, the delivery mechanisms for RNA editing tools into target cells are still under development, with issues related to efficiency and specificity yet to be fully resolved. Additionally, ensuring the edited RNA's stability and functional integration within the cellular machinery requires further refinement. The technology also faces hurdles in scalability and the ability to precisely target a wide range of genetic sequences with high fidelity. These technical barriers must be overcome through rigorous research and experimental validation before RNA editing can advance to later stages of technology readiness, where its practical applications in clinical settings can be fully explored and realized.
In the Short-Term, RNA editing is poised for significant advancements in precision medicine. Over the next few years, development in CRISPR-Cas systems will enhance the accuracy and efficiency of RNA modifications. This progress aims to address genetic disorders by enabling temporary edits without altering the DNA itself, offering a safer alternative for therapeutic interventions. The focus will also be on improving delivery mechanisms to target cells more effectively, reducing off-target effects and increasing treatment specificity. The Mid-Term phase of RNA editing technology will likely witness the integration of artificial intelligence and machine learning algorithms to predict and model RNA editing outcomes with greater precision. This period will see RNA editing moving beyond therapeutic applications to agriculture, where it could be used to create crops that are more resistant to diseases and environmental stresses. Additionally, the development of scalable RNA editing platforms is anticipated, making these technologies more accessible to researchers and clinicians, thereby accelerating the pace of discovery and application in various fields. Looking into the Long-Term, we can expect the emergence of revolutionary RNA editing techniques that could potentially cure genetic diseases by correcting mutations at the RNA level with unparalleled precision and minimal side effects. The long-term horizon also holds the promise of personalizing medicine to an individual’s genetic makeup, allowing for highly customized treatments. Furthermore, the ethical and regulatory framework governing RNA editing will likely have evolved to better address the rapid technological advancements, ensuring that the benefits of these technologies are realized responsibly and equitably.
Some interesting questions that has been asked about the results you have just received for RNA Editing
What are related technologies to RNA Editing?
Based on our calculations related technologies to RNA Editing are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of RNA Editing?
Which industries are mostly working on RNA Editing?
The most represented industries which are working in RNA Editing are Biotechnology, Science and Engineering, Health Care, Financial Services, Lending and Investments
How does ensun find these RNA Editing Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
